

OPEN ACCESS

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/ijgc-2022-004039>).

Leiden University Medical Center, Leiden, The Netherlands

Correspondence to

RAINBO Research Consortium, Leiden University Medical Center, Leiden, Netherlands; n.horeweg@lumc.nl

Accepted 31 October 2022

Published Online First
20 December 2022



© IGCs and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.

To cite: RAINBO Research Consortium. *Int J Gynecol Cancer* 2023;**33**:109–117.

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

RAINBO Research Consortium

ABSTRACT

Background The endometrial cancer molecular classification has been integrated into the 2020 World Health Organization (WHO) diagnostic classification and European treatment guidelines, and provides direction towards more effective and less toxic adjuvant treatment strategies for women with endometrial cancer.

Primary Objective(s) The RAINBO program of clinical trials will investigate four molecular class-directed adjuvant treatment strategies following surgical resection to either increase cure rates through the addition of novel targeted therapies or safely reduce toxicity and improve quality of life through treatment de-escalation.

Study Hypothesis Molecular-directed adjuvant treatment strategies will improve clinical outcomes and reduce toxicity of unwarranted therapies in women with endometrial cancer. The overarching and translational research RAINBO program will advance knowledge of predictive and prognostic (bio)markers that will improve prognostication and treatment allocation.

Trial Design The RAINBO program is a platform of four international clinical trials and an overarching research program. The randomized phase III p53abn-RED trial for women with invasive stage I–III p53abn endometrial cancer compares adjuvant chemoradiation followed by olaparib for 2 years with adjuvant chemoradiation alone. The randomized phase III MMRd-GREEN trial for women with stage II (with lymphovascular space invasion (LVSI)) or stage III mismatch repair-deficient (MMRd) endometrial cancer compares adjuvant radiotherapy with concurrent and adjuvant durvalumab for 1 year to radiotherapy alone. The randomized phase III NSMP-ORANGE trial is a treatment de-escalation trial for women with estrogen receptor positive stage II (with LVSI) or stage III no specific molecular profile (NSMP) endometrial cancer comparing radiotherapy followed by progestin for 2 years to adjuvant chemoradiation. The *POLE*mut-BLUE trial is a phase II trial in which the safety of de-escalation of adjuvant therapy is investigated for women with stage I–III *POLE*mut endometrial cancer: no adjuvant therapy for lower-risk disease and no adjuvant therapy or radiotherapy alone for higher-risk disease. The overarching RAINBO program will combine data and tumor material of all participants to perform translational research and evaluate molecular class-based adjuvant therapy in terms of efficacy, toxicity, quality of life, and cost-utility.

Major Inclusion/Exclusion Criteria Inclusion criteria include a histologically confirmed diagnosis of endometrial cancer treated by hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy

or sentinel lymph node biopsy, with no macroscopic residual disease after surgery and no distant metastases, and molecular classification according to the WHO 2020 algorithm.

Primary Endpoint(s) Recurrence-free survival at 3 years in the p53abn-RED, MMRd-GREEN, and NSMP-ORANGE trials and pelvic recurrence at 3 years in the *POLE*mut-BLUE trial.

Sample Size The p53abn-RED trial will include 554 patients, the MMRd-GREEN trial 316, the NSMP-ORANGE trial 600, and the *POLE*mut-BLUE trial 145 (120 for lower-risk disease and approximately 25 for higher-risk disease). The overarching research program will pool the four sub-trials resulting in a total sample size of around 1600.

Estimated Dates for Completing Accrual and Presenting Results The four clinical trials will have different completion dates; main results are expected from 2028.

Trial Registration Number The RAINBO program is registered at clinicaltrials.gov (NCT05255653).

INTRODUCTION

Endometrial cancer is the most common gynecological cancer in high-income countries and its incidence and mortality are rising, at least in part, due to increased obesity and aging of the population.¹ Primary treatment for endometrial cancer is total hysterectomy with bilateral salpingo-oophorectomy with or without staging by a sentinel lymph node biopsy, systematic lymphadenectomy or additional biopsies.¹ About 15–20% of patients have a high risk of recurrence and disease-related death.¹ For these patients, radiotherapy and/or adjuvant chemotherapy is recommended.²

Endometrial cancer is classified into four distinct molecular subtypes: (1) '*POLE*mut' endometrial cancer, characterized by pathogenic mutations in the exonuclease domain of DNA polymerase- ϵ , resulting in an ultra-high tumor mutational burden and an excellent clinical outcome; (2) mismatch repair-deficient (MMRd) endometrial cancer, which has loss of mismatch repair proteins, resulting in microsatellite instability and an intermediate prognosis; (3) p53abn endometrial cancer, with a low tumor mutational burden and high somatic copy-number alterations resulting in poor clinical outcomes; and (4) no specific molecular profile (NSMP) endometrial cancer, which

Clinical trial

has no single identifying molecular feature and tumor stage- and grade-dependent outcomes.³ The four molecular classes have been implemented in the latest ESGO/ESTRO/ESP and ESMO and guidelines, and when available are used in addition to standard clinicopathological risk factors to classify patients with endometrial cancer into risk groups that form the basis for endometrial cancer treatment recommendations.²

Although these guidelines are expected to improve prognostication and decisions on adjuvant treatment, challenges remain. First, risks of recurrence and death are high in some sub-groups—for example, in p53abn endometrial cancer and stage III MMRd endometrial cancer. Second, the currently recommended treatments lead to substantial morbidity for patients.⁴ Last, insufficient data are available for some sub-groups to allocate the patient to a prognostic risk group and provide treatment recommendations. Examples are stage III *POLE*mut endometrial cancer and stage II–III MMRd and NSMP endometrial cancer with clear cell histology. Prospective clinical trials of molecular class-directed adjuvant treatment strategies are urgently needed to optimize tumor control, reduce toxicity, improve quality of life, and collect outcome data on the rarer subtypes of endometrial cancer.

Applying the molecular framework in endometrial cancer, the RAINBO Consortium has designed a platform of clinical trials to prospectively investigate different treatment strategies for each of the four molecular classes: the RAINBO program. These clinical trials have been designed to assess adjuvant therapy regimens specific to the molecular classes, examining efficacy or toxicity and quality of life.

Rationale for the Four Clinical Trials of the RAINBO Program

p53abn-RED Trial

Twenty-three percent of women participating in PORTEC-3 had p53abn endometrial cancer, and their prognosis was poor despite the benefit of the addition of concurrent and adjuvant chemotherapy to radiotherapy (5-year recurrence-free survival (RFS) 59% vs 36%, hazard ratio (HR) 0.52, 95% CI 0.30 to 0.91, $p=0.021$).⁵ The Cancer Genome Atlas study described remarkable genomic similarities between p53abn endometrial cancer and high-grade serous ovarian cancer. They both harbor high genomic instability, low mutation loads and almost universal *TP53* mutations, suggesting opportunities for overlapping treatment paradigms.⁶ A more recent evaluation by the Cancer Genome Atlas study showed that 25% of endometrial cancer cases had genomic instability scores suggestive of homologous recombination deficiency (HRD), and these were almost exclusively *TP53*-mutated tumors.⁷ We recently confirmed using a functional assay that HRD is present in about half the cases of p53abn endometrial cancer.⁸ PARP inhibitors have been developed in high-grade ovarian cancer because of the high frequency of molecular alterations in the homologous recombination DNA damage repair pathway, and are now part of standard of care. We hypothesize that 2 years of PARP inhibition as maintenance therapy after chemoradiation will improve RFS compared with chemoradiation only in patients with p53abn stage I–III endometrial cancer.

MMRd-GREEN Trial

Thirty-three percent of women participating in PORTEC-3 had MMRd endometrial cancer, and no benefit of the addition of chemotherapy to radiotherapy was observed (5-year RFS 68% vs 76%,

HR 1.29, 95% CI 0.68 to 2.45, $p=0.43$).⁵ MMRd endometrial cancer is hypermutated and frequently has dense intra-tumoral CD8+ T cell infiltrates and tertiary lymphoid structures.⁹ Counterbalancing this active immune phenotype, high levels of immune checkpoint molecules such as PD-1 and PD-L1 are expressed. Several immune checkpoint inhibitors have shown benefit and are now approved in advanced MMRd endometrial cancer. In patients with advanced microsatellite unstable/MMRd endometrial cancer, PD-(L)1 inhibitors have shown objective response rates of around 45% and durable anti-tumor activity and manageable toxicity.¹⁰ We therefore hypothesize that adjuvant radiotherapy combined with and followed by a year of immune checkpoint inhibition will reduce the risk of recurrence in patients with high-risk MMRd endometrial cancer compared with radiotherapy alone.¹¹

NSMP-ORANGE Trial

Thirty-two percent of woman included in PORTEC-3 had NSMP endometrial cancer, and a 5-year RFS of 80% after chemoradiation and 68% after radiotherapy was found.⁵ This apparent improvement in RFS did not reach statistical significance (HR 0.68, 95% CI 0.36 to 1.30, $p=0.25$). This leaves some uncertainty as to the clinical benefit of chemotherapy, particularly when considering the potential negative impact on functioning and symptoms.¹² For example, in PORTEC-3, grade ≥ 3 toxicity was observed in 61% after chemoradiation compared with 13% after radiotherapy alone ($p<0.0001$) and, even 5 years after chemoradiation, women still reported significantly more grade 2 toxicity.^{4,12} Therefore, research into less toxic alternatives for chemotherapy is of importance. Hormonal treatment has a relatively mild toxicity profile and is an attractive alternative because the majority of high-risk NSMP endometrial cancers are of the endometrioid histotype and hormone receptor positive (estrogen receptor 85%, progesterone receptor 73%).¹³ Hormonal treatment is currently the first-line systemic therapy in patients with recurrent and metastatic endometrial cancer without rapidly progressive disease. Progestins are generally recommended,² and yield an objective response in about a quarter of patients and clinical benefit in about half of patients.¹⁴ There are no modern era trials of adjuvant hormone therapy in endometrial cancer. A meta-analysis of seven randomized studies carried out mainly in the 1980s showed no significant impact on overall survival.¹⁵ However, most of the participants had low- and intermediate-risk disease. It is also likely that about half of the patients included in these trials had molecular profiles less likely to benefit from hormonal treatment (p53abn, MMRd, *POLE*mut). By selecting patients with tumors likely to respond to hormone manipulation, we will test the hypothesis that, in patients with hormone receptor positive high-risk NSMP endometrial cancer, radiotherapy with maintenance progesterone tablets for 2 years will be as effective as chemoradiation while reducing toxicity and improving quality of life.

*POLE*mut-BLUE Trial

*POLE*mut endometrial cancer is the least common molecular class of endometrial cancer (~10%), and excellent patient outcomes are consistently demonstrated with this tumor feature, regardless of adjuvant therapy. *POLE*mut endometrial cancer is characterized by a high tumor mutational burden and has one of the 11 pathogenic mutations in the exonuclease domain of the *POLE* gene.¹⁶ Endometrial cancer with non-pathogenic *POLE* mutations has been shown

to have significantly more disease-related events and is often associated with mismatch-repair deficiency.¹⁷ A meta-analysis of 294 patients with pathogenic *POLE* mutations showed that 4.1% had disease recurrence or progression and only 1.0% died due to their disease.¹⁷ There was no apparent benefit in clinical outcomes from receiving adjuvant therapy.¹⁷ An *in vitro* study showed that pathogenic *POLE* mutations did not increase sensitivity to radiotherapy or chemotherapeutics.¹⁸ Women with high-risk *POLE*mut endometrial cancer included in PORTEC-3 had excellent outcomes regardless of the addition of chemotherapy (5-year RFS 100% vs 97%, $p=0.64$). A recent Danish population-based study confirmed that the prognosis of women with *POLE*mut endometrial cancer is excellent even in the absence of adjuvant treatment.⁵ These data support a phase II clinical trial on treatment de-escalation for *POLE*mut endometrial cancer. In the RAINBO *POLE*mut-BLUE trial, omission of adjuvant therapy will be investigated in lower-risk disease and de-escalation of treatment (observation or radiotherapy, but not chemoradiation) in higher-risk disease.

In the RAINBO trial program we aim to improve clinical outcomes and reduce toxicity of unwarranted therapies in women with endometrial cancer by molecular-directed adjuvant treatment strategies. In addition, we aim to discover and validate predictive and prognostic (bio)markers to improve prognostication and treatment allocation.

METHODS

Trial Design

The RAINBO program is a platform of four clinical trials where patients are included according to the molecular class of their tumor (Figure 1). The RAINBO Consortium structure is provided in Figure 2 and shows how the four trials are managed by a Central Steering Committee and connected to a common Advisory Committee, Statistics Committee, and Translational Research Committee. The RAINBO program is designed according to the ENGOT model D, with Leiden University Medical Center in the Netherlands as the sponsor of the RAINBO program and the MMRd-GREEN trial.

The p53abn-RED trial is led from France by the sponsor Institute Gustave Roussy. The NSMP-ORANGE trial will be led from the UK and sponsored by University College London pending funding applications. The *POLE*mut-BLUE trial is led from Canada and sponsored by the Canadian Cancer Trials Group.

Funding for the RAINBO program has been obtained from the French Cancer Institute (Institut National du Cancer), the Dutch Cancer Society (KWF Kankerbestrijding), the Canadian Institutes for Health Research and AstraZeneca. Ethical approval will be obtained from the Institutional Review Board at each participating center and/or via Clinical Trials Information System of the European Medicines Agency in European Union member states before start of accrual.

The p53abn-RED trial is an international phase III superiority trial in which patients with invasive stage I–III p53abn endometrial cancer are randomized (1:1) to adjuvant chemoradiation followed by olaparib (300 mg twice daily, orally) for 2 years or adjuvant chemoradiation alone. Patients will be recruited at 20 participating centers in France and at international sites.

The MMRd-GREEN trial is an international phase III superiority trial in which women with stage II with substantial lymphovascular space invasion (LVSI) or stage III MMRd endometrial cancer are randomized (1:1) to adjuvant pelvic radiotherapy combined with and followed by the PD-L1 inhibitor durvalumab (13 cycles of 1500 mg intravenously, every 4 weeks) for 1 year or radiotherapy alone. Patient accrual has started; activation of 12 centers in the Netherlands and international sites is ongoing.

The NSMP-ORANGE trial is an international phase III non-inferiority trial in which patients with stage II (LVSI+) or stage III NSMP endometrial cancer are randomized (1:1) to adjuvant radiotherapy followed by progesterone tablets (either medroxyprogesterone acetate or megestrol acetate) for 2 years or adjuvant chemoradiation alone. Patients will be included in 25–30 centers in the UK and international sites.

The *POLE*mut-BLUE trial (also known as CTG EN.10 TAPER arm A POLE) is an international phase II trial investigating the safety of de-escalation of adjuvant therapy: no adjuvant therapy for select stage I–II disease (main cohort, see online supplemental data 1) and




Figure 1 Design of the RAINBO program. ER, estrogen receptor status; LVSI, lymphovascular space invasion; MMRd, mismatch repair deficient; NSMP, no specific molecular profile; p53abn, p53 abnormal; *POLE*mut, DNA polymerase- ϵ mutated; R, randomization; RAINBO, Refining Adjuvant treatment IN endometrial cancer Based On molecular features.

Clinical trial




Figure 2 RAINBO Consortium structure. MMRd, mismatch repair deficient; NSMP, no specific molecular profile; p53abn, p53 abnormal; POLEmut, DNA polymerase-ε mutated; RAINBO, Refining Adjuvant treatment IN endometrial cancer Based On molecular features.

no adjuvant therapy or radiotherapy only for higher-risk stage I–III disease (exploratory cohort). Patient accrual has started in Canada, where >15 centers will open in addition to international sites.

The four clinical trials have common inclusion and exclusion criteria, synchronized measurements, and uniform prospective registration of a set of common data elements (Table 1). This

enables a combination of the data and tumor material of the four trials for the overarching program and translational studies.

In the RAINBO overarching research program, personalized molecular profile-direct treatment (Group A) and standard treatment (Group B) will be assessed in terms of efficacy, toxicity, quality of life, and cost-utility. Data of all participants of the p53abn-RED,

Table 1 Registration of common data elements in the RAINBO program

	Baseline	Tx	Time since registration in months						
			2–3	6	12	18	24	36	60
Informed consent	x								
Tumor tissue collection	x								
Patient age, height	x								
Patient weight, WHO performance status	x				x*		x*	x	x*
Comorbidity (NCI)	x								
Chest/abdominal/pelvic CT/MRI and/or PET-CT	x			x*	x*	x*	x*	x	
Pathology assessment	x								
Molecular classification	x								
Treatment characteristics (if applicable)		x							
Selected toxicities (CTCAE v5.0)	x		x	x	x	x*	x*	x	x*
PR-QoL (EORTC QLQ C30 and EN24)	x		x*	x*	x	x*	x*	x	x*
Follow-up endpoints	Vaginal, pelvic, para-aortic lymph node and abdominal/distant recurrences and death, and cause of death								
Off study	Date and reason (eg, IC withdrawal, lost to follow-up, death)								

*Optional, the trial-specific protocol will indicate whether time point is included or not. CTCAE, Common Terminology Criteria for Adverse Events; EORTC, European Organization for Research and Treatment of Cancer; IC, informed consent; NCI, National Comorbidity Index; PET, positron-emission tomography; PR-QoL, patient reported quality of life; QLQ C30 and EN24, quality of life questionnaire common and endometrial cancer-specific modules; Tx, treatment.




Figure 3 Inclusion algorithm of the RAINBO program. Assessment of the molecular classification must be performed according to the World Health Organization 2020 classification of endometrial cancer.³

¹POLE status is assessed by DNA sequencing of the POLE gene and at least the five most common (but preferably all) 11 variants as described by León-Castillo et al¹⁶ which are considered pathogenic. ²MMR deficiency is assessed by IHC and is defined by loss of one or more of the four MMR proteins (MLH1, PMS2, MSH2 and MSH6). ³p53 status is assessed by IHC and three abnormal patterns are defined: mutant overexpression, null pattern, and cytoplasmatic expression. DNA sequencing of the entire *TP53* gene to detect pathogenic variants is an accepted alternative. ⁴ER status is assessed by IHC and is considered positive if expression is observed in >10% of the tumor tissue. ER, estrogen receptor; IHC, immunohistochemistry; MMRd, mismatch repair deficient; p53abn, p53 abnormal; POLEmut, DNA polymerase-ε mutant; RAINBO, Refining Adjuvant treatment IN endometrial cancer Based On molecular features.

MMRd-GREEN, and NSMP-ORANGE sub-trials will be investigated by treatment (Figure 3).

The central RAINBO tumor tissue repository will form a strong basis for future translational research studies directed at identifying biomarkers that can further refine the molecular classification and predict targeted therapy benefit.

Participants

The inclusion and exclusion criteria of the RAINBO program apply to all women included in the four RAINBO clinical trials. In addition, trial-specific inclusion and exclusion criteria are provided in online supplemental data 1. Assessment of the *POLE*, MMR, p53, and estrogen receptor status are mandatory to determine for which trial women are eligible. The inclusion algorithm of the RAINBO program is shown in Figure 3. The protocol for the assessment of the molecular classification is provided in online supplemental data 2. The requirements for surgery, radiotherapy and chemotherapy are set out in online supplemental data 3.

Inclusion Criteria

- ▶ Histologically confirmed diagnosis of endometrial cancer with one of the following histotypes: endometrioid endometrial carcinoma, serous endometrial carcinoma, uterine clear cell carcinoma, dedifferentiated and undifferentiated endometrial carcinoma, uterine carcinosarcoma, and mixed endometrial carcinomas of the aforementioned histotypes.

- ▶ Full molecular classification performed according to the WHO 2020 diagnostic algorithm.³
- ▶ Hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease after surgery.
- ▶ No distant metastases as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan).
- ▶ Age ≥18 years.
- ▶ WHO performance status 0, 1 or 2.
- ▶ Expected start of adjuvant treatment (if applicable) within 10 weeks after surgery.
- ▶ Patients must be accessible for treatment and follow-up.
- ▶ Written informed consent for participation in one of the RAINBO trials, permission for the contribution of a tissue block for translational research, and permission for the use and sharing of data for the overarching research program.

Exclusion Criteria

- ▶ History of another primary malignancy, except for non-melanoma skin cancer, in the past 5 years.
- ▶ Prior pelvic radiation.

Primary Endpoints

The primary endpoint of the p53abn-RED, MMRd-GREEN, and NSMP-ORANGE trials is 3-year RFS. The primary endpoint of

Clinical trial




Figure 4 Sample size of the RAINBO clinical trials and overarching research program. CRT, chemoradiotherapy; ER, estrogen receptor; HT, hormonal therapy; LSVI, lymphovascular space invasion; MI, myometrial invasion; RAINBO, Refining Adjuvant treatment IN endometrial cancer Based On molecular features; RT, radiotherapy; Tx, therapy; tox, toxicity; QoL, quality of life. *Data on *POLEmut*-BLUE trial participants will be pooled in Group A or B depending on tumor characteristics and received adjuvant treatment strategy.

the *POLEmut*-BLUE trial is 3-year pelvic recurrence. Secondary endpoints of the p53abn-RED, MMRd-GREEN, and NSMP-ORANGE trials are 5-year RFS, 3- and 5-year pelvic recurrence-free survival. Secondary endpoints of the *POLEmut*-BLUE trial are 5-year pelvic recurrence, 3- and 5-year RFS, decisional conflict, and fear of recurrence. Other secondary endpoints of all four RAINBO trials include 3- and 5-year vaginal recurrence-free survival, distant recurrence-free survival, endometrial cancer-specific survival, overall survival, treatment-related toxicity (using the Common Terminology Criteria for Adverse Events (CTCAE) version 5) and health-related quality of life (using the common and endometrial cancer European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires C30 and EN24). Endpoints of the overarching RAINBO research program are 3-year RFS, vaginal, pelvic, and distant recurrence-free survival, endometrial cancer-specific and overall survival, treatment-related toxicity, quality of life and cost-utility. The p53abn-RED, MMRd-GREEN, NSMP-ORANGE, and *POLEmut*-BLUE trials each have predefined biomarker studies directed at, respectively, HRD status, immune phenotype, hormone receptor expression, and *POLE* mutations. In addition, formalin-fixed paraffin-embedded tumor tissue from all four trials will be collected to establish a central biobank including DNA and RNA repositories and scanned histological images for translational studies.

Sample Size

A detailed description of the sample size calculations and the underlying assumptions for all four clinical trials is provided in online supplemental data 4.

The p53abn-RED trial will randomize (1:1) 554 patients. The trial will have 80% power (two-sided $\alpha=0.05$) to detect a HR of ≤ 0.67 from a 3-year RFS rate of 64.6% in the control arm using a log-rank test, with an interim analysis for efficacy at 70% information,

assuming accrual duration of 36 months with an additional follow-up of 30 months and a drop-out rate of 5%.

The MMRd-GREEN trial will randomize (1:1) 316 patients. The trial will have 80% power (two-sided $\alpha=0.05$) to detect a HR ≤ 0.58 from a 3-year RFS rate of 65% in the control arm using a log-rank test, assuming accrual duration of 30 months with a 30-month follow-up period and a drop-out rate of 2%. No interim analysis is planned; an independent data monitoring committee (IDMC) will routinely monitor recurrences and adverse events.

The NSMP-ORANGE trial will randomize (1:1) 600 patients. Assuming a 3-year RFS rate of 82.5% in the control arm, a non-inferiority margin of 7.5 percentage points is of interest, to exclude a rate $\leq 75\%$ (ie, HR 1.495) with 80% power (one-sided $\alpha=0.05$). Patients will be recruited over 5 years with 3 years of additional follow-up, allowing for 5% dropout. Futility analyses are incorporated; conditional power will be routinely presented to the IDMC.

The *POLEmut*-BLUE trial will recruit 120 patients with select stage I-II *POLEmut* endometrial cancer in the main 'lower risk' study cohort (criteria provided in online supplemental data 1). A 3-year pelvic recurrence rate of 1% (upper 95% CI 2.4%) is assumed. If the upper 95% CI is $< 5\%$, it will be concluded that no adjuvant therapy has an acceptable low risk of pelvic recurrence (one-sided $\alpha=0.05$). Patients will be recruited over 36 months with 36 months of additional follow-up. Interim analysis for futility will be carried out when half of the person-years of follow-up have been observed. In addition, patients with 'higher-risk' *POLEmut* endometrial cancer will be accrued into an exploratory cohort (approximately 25 patients) for descriptive analysis (criteria provided in online supplemental data 1).

The sample size of the overarching RAINBO research program will be around 1600 patients (Figure 4). Power calculations and

graphs for efficacy, toxicity and quality of life are provided in online supplemental data 4.

Randomization and Blinding

In the p53abn-RED trial, patients will be allocated to the one of the two treatment arms using stratified randomization via an interactive web response system. Stratification factors are country, tumor stage (I–II vs III), and staging lymphadenectomy (yes vs no). In the MMRd-GREEN trial, central randomization is done by a web-based randomization application with stratification for participating center, tumor grade (1–2 vs 3), and staging lymphadenectomy (yes vs no) using a biased coin minimization procedure. In the NSMP-ORANGE trial, patient randomization is done by a remote data capture system using a minimization algorithm which will adjust the probability of treatment assignment to minimize imbalance within the stratification factors (center, stage, and lymphadenectomy/sentinel node biopsy) as well as incorporating a random element. In the *POLE*mut-BLUE trial, patients are not randomized. Blinding will not be applied in any of the RAINBO clinical trials.

Statistical Methods

Time-to-event analysis using the Kaplan–Meier method and Cox proportional hazards models will be performed to analyze the primary endpoint of the p53abn-RED, MMRd-GREEN, and NSMP-ORANGE trials. Competing risk analysis will be performed for the primary endpoint of the *POLE*mut-BLUE trial. Detailed descriptions of the statistical methods of the primary and secondary endpoints of the four RAINBO sub-trials and the overarching research program are given in online supplemental data 5.

DISCUSSION

The recent integration of the molecular classes in the risk stratification and treatment recommendations of patients with endometrial cancer is expected to improve prognostication, shared decision-making, and reduce over- and under-treatment. Nonetheless, subgroups with a poor prognosis remain, even with multimodality treatment.⁵ Moreover, many patients will suffer from treatment-related morbidity impacting on quality of life.^{4,12} To further improve treatment of patients with endometrial cancer, clinical trials are needed that investigate more effective treatments in those at highest risk, and less toxic, safe alternative treatment strategies in those who do not benefit from the current standard of care.

RAINBO is an innovative practice-defining program consisting of three randomized clinical trials of novel adjuvant treatment strategies for women with high-risk p53abn endometrial cancer, MMRd endometrial cancer, and NSMP endometrial cancer and one clinical trial of treatment de-escalation for women with *POLE*mut endometrial cancer. In each trial, oncological outcomes, survival, toxicity, and quality of life will be uniformly registered to enable pooling for the overarching research program. As such, RAINBO will give a comprehensive answer to the question whether molecular-directed treatment is more effective, less toxic, and yields better quality of life than the current standard of care for women with endometrial cancer. Formalin-fixed paraffin-embedded tumor tissue blocks will be prospectively collected to create a biobank for trial-specific and overarching translational research. The translational research program of RAINBO is expected to contribute to better patient

stratification, both for risk assessment and for precision treatment allocation through identification and validation of new prognostic and predictive (bio)markers. Further, we anticipate that this work will provide an insight into the (molecular) biology of endometrial cancer and its interaction with the immune system. In short, the RAINBO program will deliver unique results that will shape the future of endometrial cancer research and management.

Twitter RAINBO Research Consortium @RAINBOprogram

Acknowledgements We gratefully acknowledge the patient advocacy group ‘Olijf’; the Institute Gustave Roussy Trial Center, Comprehensive Cancer Center the Netherlands (IKNL); Cancer Research UK and UCL Cancer Trials Centre and L Hughes and K Chan; the Canadian Clinical Trials Group (CCTG) and A Fyles, F Huang, M Carey, M Barkati, S Ferguson, and A Urton; the PORTEC-3 Trial Group; and the TransPORTEC Research Consortium.

Collaborators RAINBO Research Consortium: Individual names of the members of the collaborator group: Steering Group (alphabetical): T Bosse,¹ CL Creutzberg,² EJ Crosbie,³ K Han,⁴ N Horeweg,² A Leary,⁵ JR Kroep,⁶ JN McAlpine,⁷ ME Powell.⁸ Translational Committee (alphabetical): F Blanc-Durand,⁵ T Bosse,¹ M de Bruyn,⁹ DN Church,^{10,11} N Horeweg,² VH Koelzer,^{12,13} S Kommos,¹⁴ A Leary,⁵ JN McAlpine,⁷ N Singh,¹⁵ Statistical Committee (alphabetical): A Bardet,^{16,17} N Counsell,¹⁸ N Horeweg,² H Putter,¹⁹ D Tu,²⁰ Advisory Committee (alphabetical): R Edmondson,³ C Gordon,²¹ J Ledermann,²² P Morice,²³ H MacKay,²⁴ H Nijman,⁹ RA Nout,²⁵ VTHBM Smit,¹ H White.²⁶ Country Champions (alphabetical): J Alexandre,^{27,28} SM de Boer,² I Boere,²⁹ R Cooper,³⁰ JL Ethier,^{31,32} JS Frenel,³³ J McGrane,³⁴ A Taylor,³⁵ S Welch,³⁶ AM Westermann.³⁷ Trial Management (alphabetical): H Dijkstra-van der Linden,³⁸ L Farrelly,¹⁸ A Feeney,¹⁸ M Kaya,² W Liu,²⁰ A Melis,³⁹ F Ngadjieu-Tchouatieu,³⁹ W Parulekar,²⁰ K Verhoeven-Adema.³⁸ Writing Committee: N Horeweg,² ME Powell,⁸ K Han,⁴ JR Kroep,⁶ F Blanc-Durand,⁵ S Welch,³⁴ A Bardet,^{16,17} N Counsell,¹⁸ H Putter,¹⁹ D Tu,²⁰ N Singh,¹⁵ DN Church,^{10,11} S Kommos,¹⁴ M de Bruyn,⁹ H Nijman,⁹ CL Creutzberg,² JN McAlpine,⁷ T Bosse,¹ EJ Crosbie,³ H MacKay,²⁴ A Leary.⁵

Affiliations of the participants of the RAINBO research consortium: ¹Department of Pathology, Leiden University Medical Center, the Netherlands. ²Department of Radiation Oncology, Leiden University Medical Center, the Netherlands. ³Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary’s Hospital, Manchester, UK. ⁴Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Radiation Oncology, Toronto, Canada. ⁵Department of Medical Oncology, Gustave Roussy Cancer Center, Université Paris Saclay, Cancer Medicine and Gynecological Tumor Translational Research Lab, Villejuif, France. ⁶Department of Medical Oncology, Leiden University Medical Center, the Netherlands. ⁷Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada. ⁸Department of Clinical Oncology, Barts Health NHS Trust, London, UK. ⁹Department of Gynaecology, University Medical Center Groningen, Groningen University, Groningen, the Netherlands. ¹⁰Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ¹¹Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, UK. ¹²Department of Pathology and Molecular Pathology, University Hospital Zürich, University of Zürich, Zürich, Switzerland. ¹³Department of Oncology and Nuffield Department of Medicine, University of Oxford, Oxford, UK. ¹⁴Department of Women’s Health, University of Tübingen, Tübingen, Germany. ¹⁵Department of Cellular Pathology, Barths Health NHS Trust, London, UK. ¹⁶Bureau of Biostatistics and Epidemiology, University Paris-Saclay, Gustave-Roussy, Villejuif, France. ¹⁷Oncostat U1018, Inserm, University Paris-Saclay, Ligue Contre le Cancer, Villejuif, France. ¹⁸Cancer Research UK and University College London Cancer Trials Centre, University College London, London, UK. ¹⁹Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. ²⁰Canadian Cancer Trials Group, Queen’s University, Kingston, Ontario, Canada. ²¹Patient Representative, Canadian Cancer Clinical Trials Group, Queen’s University, Kingston, Ontario, Canada. ²²Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute and UCL Hospitals, London, UK. ²³Department of Gynaecologic Surgery, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France. ²⁴Department of Medical Oncology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. ²⁵Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. ²⁶Patient Representative, Peaches Patient Voices, Manchester, UK. ²⁷Centre de Recherche des Cordeliers, Equipe labélisée Ligue Contre le Cancer, Sorbonne Université, Université de Paris, INSERM, Paris, France. ²⁸Department of Medical Oncology, Hôpital Cochin, Institut du Cancer Paris, Paris, France. ²⁹Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the

Clinical trial

Netherlands.³⁰Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. ³¹Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Ontario, Canada. ³²Department of Oncology, Queen's University, Kingston, Ontario, Canada. ³³Department of Medical Oncology, Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-Herblain, France. ³⁴Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK. ³⁵Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK. ³⁶Division of Medical Oncology, Western University, London, Ontario, Canada. ³⁷Department of Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. ³⁸Comprehensive Cancer Center the Netherlands (KNL), Leiden, the Netherlands. ³⁹Clinical Research Department, Institute Gustave Roussy, Chevilly-Larue, France.

Contributors The current work is the result of the collaborative effort of the RAINBO Research Consortium. The Consortium is led by the Steering Group consisting of the following members (in alphabetical order): T Bosse, CL Creutzberg, EJ Crosbie, K Han, N Horeweg, A Leary, JR Kroep, JN McAlpine, ME Powell. The Translational Committee is responsible for the design and conduct of translational studies with the tumor materials obtained from the participants of the RAINBO program and consists of the following members (in alphabetical order): F Blanc-Durand, T Bosse, M de Bruyn, DN Church, N Horeweg, VH Koelzer, S Kommos, A Leary, JN McAlpine, N Singh. The Statistical Committee is responsible for the design and analyses of the outcomes of the four RAINBO clinical trials and the overarching research program and consists of the following members (in alphabetical order): A Bardet, N Counsell, N Horeweg, H Putter, D Tu. The Advisory Committee with representation from international experts and patient advocates provides the Steering Group with independent advice and consists of the following members (in alphabetical order): R Edmondson, C Gordon, J Ledermann, P Morice, H MacKay, H Nijman, RA Nout, VTHBM Smit, H White. The Country Champions are responsible for the execution of the RAINBO clinical trials in the non-leading countries (in alphabetical order): J Alexandre, SM de Boer, I Boere, R Cooper, JL Ethier, JS Frenel, J McGrane, A Taylor, S Welch, AM Westermann. The RAINBO clinical trials are managed by (in alphabetical order): H Dijcker-van der Linden, L Farrelly, A Feeney, M Kaya, W Liu, A Melis, F Ngadjjeu-Tchouatieu, W Parulekar, K Verhoeven-Adema. The current manuscript has been written collaboratively by all the Writing Committee members: N Horeweg, ME Powell, K Han, JR Kroep, F Blanc-Durand, S Welch, A Bardet, N Counsell, H Putter, D Tu, N Singh, DN Church, S Kommos, M de Bruyn, H Nijman, CL Creutzberg, JN McAlpine, T Bosse, EJ Crosbie, H MacKay, A Leary. NH acts as guarantor for this publication and takes responsibility for its content. The sponsors are responsible for the conduct of the clinical trials of the RAINBO program.

Funding A research project grant from the Dutch Cancer Society (KWF 13403) was awarded for partial funding of the MMRd-GREEN trial and the RAINBO overarching research program. An unrestricted educational grant from the French Institut National du Cancer was awarded for partial funding of the p53abn-RED trial and French participation in the RAINBO program. An unrestricted educational grant was provided by AstraZeneca for partial funding of the p53abn-RED trial. Two grants from the Canadian Institutes for Health Research were awarded for, respectively, the POLEmut-BLUE trial (CCTG EN.10 TAPER arm A POLE) and Canadian participation in the MMRd-GREEN trial. Durvalumab and olaparib were provided by AstraZeneca.

Competing interests J Alexandre reports grants paid to his institution by MSD and Janssen; consulting fees to him by MSD, AstraZeneca, GSK, Eisai, and Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events to him by MSD, AstraZeneca, GSK, Clovis, and Novartis; support for attending meetings and/or travel to him by AstraZeneca and Novartis. SM de Boer reports a research grant paid to her institution by Varian Medical Systems. T Bosse reports research project funding by the Dutch Cancer Society (KWF). DN Church has participated in an advisory board for MSD and has received research funding from HalioDx (on behalf of the TransSCOT consortium). CL Creutzberg reports research grants from the Dutch Cancer Society (KWF) for the conduct of the PORTEC trials and the RAINBO program. JL Ethier reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events by Merck, GSK and AstraZeneca and participation in these companies' Advisory Boards. JS Frenel reports having personally received consulting fees and support for attending meetings and/or travel by Pfizer, Lilly, Novartis, AstraZeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, and Seagen. Payment or honoraria were personally received for lectures, presentations, speaker bureaus, manuscript writing or educational events from Lilly, Novartis, AstraZeneca, Gilead, Daiichi Sankyo, and Seagen. C Gordon reports being a member of the Canadian Cancer Clinical Trials Group as member of the Patients' Representatives Committee on a volunteer basis. K Han reports research grants from the Canadian

Institutes of Health Research Project Grant and Princess Margaret Hospital Foundation, participating on the AstraZeneca Cervical Cancer Radiation Oncology Advisory Board (October 2021), and being Endometrial Cancer Working Group Co-Chair of the Canadian Cancer Trials Group. N Horeweg reports research grants paid to her institution from the Dutch Cancer Society (KWF) and an unrestricted research grant by Varian for the RAINBO program and other unrelated research projects. VH Koelzer is principal investigator in a public-private partnership with Roche unrelated to the topic of this manuscript, received research funding from the Image Analysis Group unrelated to the topic of this manuscript, served as an invited speaker on behalf of Indica Labs, and is participant of a patent application co-owned by the Netherlands Cancer Institute (NKI-AVL) and the University of Basel on the assessment of cancer immunotherapy biomarkers by digital pathology. JR Kroep reports having received study drugs and an unrestricted research grant from AstraZeneca for the conduct of the MMRd-GREEN trial, as well as a research grants from the Dutch Cancer Society and WCRF. Consulting fees were paid to the researcher's institution by AstraZeneca, MSD, GSK, Novartis and Eisai, as well as payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events by MSD and GSK. Participation on a Data Safety Monitoring Board or Advisory Board without payment for the TEIPP trial and the ALISON trial were reported. J McGrane reports having received consulting fees for participation in advisory boards of GSK, MSD and Ipsen and honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events, and for attending meetings and/or travel. A Taylor reports participation in the advisory board of MSD.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and ethical approval will be obtained in each country and/or at each participating center according to the local regulations. The first approval was given by the Medisch-Ethische Toetsingscommissie Leiden, Den Haag, Delft (registration number P21.074). All participants will give written informed consent to participate in one of the four RAINBO trials and the overarching and translational research program before taking part.

Provenance and peer review Commissioned; internally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Crosbie EJ, Kitson SJ, McAlpine JN, *et al*. Endometrial cancer. *Lancet* 2022;399:1412–28.
- Concin N, Matias-Guiu X, Vergote I, *et al*. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Int J Gynecol Cancer* 2021;31:12–39.
- WHO Classification of Tumours Editorial Board. *WHO classification of tumours, 5th Edition, Volume 4: Female genital tumours*, 2020: 252–66. <https://www.iarc.who.int/news-events/publication-of-the-who-classification-of-tumours-5th-edition-volume-4-female-genital-tumours/>
- Post CCB, de Boer SM, Powell ME, *et al*. Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial. *Int J Radiat Oncol Biol Phys* 2021;109:975–86.
- León-Castillo A, de Boer SM, Powell ME, *et al*. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. *J Clin Oncol* 2020;38:3388–97.
- Kandoth C, McLellan MD, Vandin F, *et al*. Mutational landscape and significance across 12 major cancer types. *Nature* 2013;502:333–9.

- 7 Marquard AM, Eklund AC, Joshi T, *et al.* Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. *Biomark Res* 2015;3.
- 8 de Jonge MM, Auguste A, van Wijk LM, *et al.* Frequent homologous recombination deficiency in high-grade endometrial carcinomas. *Clin Cancer Res* 2019;25:1087–97.
- 9 Horeweg N, Workel HH, Loiero D, *et al.* Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. *Nat Commun* 2022;13:1373.
- 10 Antill Y, Kok P-S, Robledo K, *et al.* Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. *J Immunother Cancer* 2021;9.
- 11 Deng L, Liang H, Xu M, *et al.* STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. *Immunity* 2014;41:843–52.
- 12 de Boer SM, Powell ME, Mileskin L, *et al.* Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol* 2016;17:1114–26.
- 13 Vermij L, Jobsen JJ, León-Castillo A. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. *MedRxiv* 2022 <https://www.medrxiv.org/content/10.1101/2022.09.13.22279853v1> 10.1101/2022.09.13.22279853
- 14 Ethier J-L, Desautels DN, Amir E, *et al.* Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. *Gynecol Oncol* 2017;147:158–66.
- 15 Martin-Hirsch PP, Bryant A, Keep SL. Adjuvant progestagens for endometrial cancer. *Cochrane Database Syst Rev* 2011;6.
- 16 León-Castillo A, Britton H, McConechy MK, *et al.* Interpretation of somatic POLE mutations in endometrial carcinoma. *J Pathol* 2020;250:323–35.
- 17 McAlpine JN, Chiu DS, Nout RA, *et al.* Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. *Cancer* 2021;127:2409–22.
- 18 Van Gool IC, Rayner E, Osse EM, *et al.* Adjuvant treatment for *POLE* proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues. *Clin Cancer Res* 2018;24:3197–203.

1 **Refining Adjuvant treatment IN endometrial cancer Based On molecular**
2 **features: the RAINBO clinical trial program**

3

4 RAINBO research consortium*

5

6 * Lists of participants and their affiliations appear at the end of the paper.

7

8 **Supplemental data**

9

10	Chapter	Page
11	1. In- and exclusion criteria	2
12	2. Requirements for surgery, radiotherapy and chemotherapy	8
13	3. Histopathology and molecular testing	12
14	4. Sample size and power	17
15	5. Statistical methods	21
16	6. RAINBO Research Consortium	23
17	7. Supplemental references	25

18 **1. In- and exclusion criteria**

19 *The p53abn-RED trial*

20 Inclusion criteria:

- 21 • Molecular classification: p53 abnormal (p53abn) endometrial cancer (EC).
- 22 • Histologically confirmed Stage III EC or stage II EC with substantial lymph vascular space invasion
23 (LVS).
- 24 • World Health Organization (WHO) performance score 0-1.
- 25 • Body weight > 30 kg.
- 26 • Adequate systemic organ function:
- 27 ○ Creatinine clearance (> 40 cc/min): Measured creatinine clearance (CL) >40 mL/min or
28 Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault
29 1976) or by 24-hour urine collection for determination of creatinine clearance.
- 30 • Adequate bone marrow function: hemoglobin >9.0 g/dl, absolute neutrophil count $\geq 1.0 \times 10^9/l$,
31 platelet count $\geq 75 \times 10^9/l$.
- 32 • Adequate liver function:
- 33 ○ bilirubin $\leq 1.5 \times$ institutional upper limit of normal (ULN). This will not apply to patients with
34 confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is
35 predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be
36 allowed only in consultation with their physician.
- 37 ○ ALT (serum glutamic-pyruvic transaminase) and/or AST (serum glutamic-oxaloacetic
38 transaminase) $\leq 2.5 \times$ ULN.

39

40 Exclusion criteria:

- 41 • Pathogenic polymerase- ϵ mutations (*POLE*mut).
- 42 • Mismatch-repair deficiency (MMRd)
- 43 • Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of
44 the investigational medicinal product.
- 45 • History of allogenic organ transplantation.
- 46 • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection,
47 symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris,
48 cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated
49 with diarrhea, or psychiatric illness/social situations that would limit compliance with study
50 requirement, substantially increase risk of incurring adverse events or compromise the ability of
51 the patient to give written informed consent.

- 52 • Any previous treatment with a PARP inhibitor, including olaparib.
- 53 • History of active primary immunodeficiency.
- 54 • History or evidence of hemorrhagic disorders within 6 months prior to randomization
- 55 • Patients with myelodysplastic syndrome/acute myeloid leukemia history or with features
- 56 suggestive of myelodysplastic syndrome/acute myeloid leukemia.
- 57 • Previous allogenic bone marrow transplant or double umbilical cord blood transplantation.
- 58 • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical
- 59 examination and radiographic findings, and tuberculosis testing in line with local practice),
- 60 hepatitis B (known positive Hepatitis B Virus [HBV] surface antigen (HBsAg) result), hepatitis C, or
- 61 human immuno-deficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved
- 62 HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of
- 63 HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase
- 64 chain reaction is negative for HCV RNA.
- 65 • Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin,
- 66 clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir,
- 67 nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g., ciprofloxacin, erythromycin,
- 68 diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2
- 69 weeks.
- 70 • Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin,
- 71 rifabutin, rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A
- 72 inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting
- 73 olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
- 74 • Patients unable to swallow orally administered medication and patients with gastrointestinal
- 75 disorders likely to interfere with absorption of the study medication.
- 76 • A medical or psychological condition which, in the opinion of the investigator, would not permit
- 77 the patient to complete the study or sign meaningful informed consent.

78

79 *The MMRd-GREEN trial*

80 Inclusion criteria:

- 81 • Molecular classification: MMRd EC.
- 82 • Histologically confirmed stage III EC or stage II EC with substantial LVSI.
- 83 • WHO performance score 0-1.
- 84 • Body weight > 30 kg.
- 85 • Adequate systemic organ function:

- 86 ○ Creatinine clearance (> 40 cc/min): measured creatinine clearance (CL) >40 mL/min or
87 ○ Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault
88 1976) or by 24-hour urine collection for determination of creatinine clearance.
- 89 ● Adequate bone marrow function: hemoglobin >9.0 g/dl. Absolute neutrophil count >1.0 X 10⁹/L,
90 platelet count >75 x 10⁹/L.
- 91 ● Adequate liver function:
- 92 ○ Bilirubin <1.5 x Institutional upper limit of normal (ULN). «This will not apply to patients with
93 confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is
94 predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be
95 allowed only in consultation with their physician.
- 96 ○ ALT (serum glutamic-pyruvic transaminase) and/or AST (serum glutamic-oxaloacetic
97 transaminase) <2.5 x ULN.
- 98
- 99 Exclusion criteria
- 100 ● Pathogenic *POLE* mutations
- 101 ● Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose
102 of the investigational medicinal product.
- 103 ● History of allogenic organ transplantation.
- 104 ● Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection,
105 symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris,
106 cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions
107 associated with diarrhea, or psychiatric illness or social situations that would limit compliance
108 with study requirement, substantially increase risk of incurring AEs or compromise the ability of
109 the patient to give written informed consent.
- 110 ● Any previous treatment with a PD(L)1 inhibitor, including durvalumab.
- 111 ● Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab. Note:
112 patients, if enrolled, should not receive a live vaccine whilst receiving the investigational
113 medicinal product or up to 30 days after the last dose of the investigational medicinal product.
- 114 ● Current or prior use of immunosuppressive medication within 14 days before the first dose of
115 durvalumab with the exceptions of:
- 116 ○ Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
- 117 ○ Systemic corticosteroids at physiologic doses not to exceed «10 mg/day» of prednisone or its
118 equivalent.
- 119 ○ Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

- 120 • History of active primary immunodeficiency.
- 121 • Active or prior documented autoimmune or inflammatory disorders (including inflammatory
- 122 bowel disease [e.g., colitis or Crohn's disease], diverticulitis [except for diverticulosis], systemic
- 123 lupus erythematosus, Sarcoidosis, or Wegener syndrome. The following are exceptions to this
- 124 criterion:
- 125 ○ Patients with vitiligo or alopecia.
- 126 ○ Patients with hypothyroidism (e.g., following Hashimoto's thyroiditis) stable on hormone
- 127 replacement.
- 128 ○ Any chronic skin condition that does not require systemic therapy.
- 129 ○ Patients without active disease in the last 5 years may be included but only after
- 130 consultation with the study physician.
- 131 • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical
- 132 examination and radiographic findings, and tuberculosis testing in line with local practice),
- 133 hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immuno-
- 134 deficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection
- 135 (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are
- 136 eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain
- 137 reaction is negative for HCV RNA.
- 138 • A medical or psychological condition which, in the opinion of the investigator, would not permit
- 139 the patient to complete the study or sign meaningful informed consent.

140

141 *The NSMP-ORANGE trial*

142 Inclusion criteria

- 143 • Non-specific molecular profile (NSMP) EC.
- 144 • Histologically confirmed stage II EC with substantial LVSI or stage III EC.
- 145 • Estrogen receptor (ER) positive EC.

146

147 Exclusion criteria

- 148 • Pathogenic *POLE* mutations
- 149 • Mismatch-repair deficiency
- 150 • p53 abnormality (IHC or sequencing of the entire *TP53* gene)

151

152

153 *The POLEmut-BLUE trial*

154 Inclusion criteria

- 155 • Pathogenic *POLE* mutation(s).
- 156 • For the low-risk group, patients must have one of the following combinations of FIGO stage,
157 grade, and LVSI:
 - 158 ○ Stage IA (not confined to polyp), grade 3, pN0*, with or without LVSI.
 - 159 ○ Stage IB, grade 1 or 2, pNx/N0, with or without LVSI.
 - 160 ○ Stage IB, grade 3, pN0*, without substantial LVSI^.
 - 161 ○ Stage II (microscopic), grade 1 or 2, pN0*, without substantial LVSI.
- 162 • For the higher-risk group, patients must have one of the following combinations of FIGO stage,
163 grade, and LVSI:
 - 164 ○ Stage IA (not confined to polyp), grade 3, pNx, with or without LVSI
 - 165 ○ Stage IB, grade 3, pNx, with or with LVSI.
 - 166 ○ Stage IB, grade 3, pN0, with substantial LVSI^.
 - 167 ○ Stage II (microscopic), grade 1 or 2, pNx, with or without LVSI.
 - 168 ○ Stage II (microscopic), grade 1 or 2, pN0, with substantial LVSI^.
 - 169 ○ Stage II (microscopic), grade 3, pNx/N0, with or without LVSI.
 - 170 ○ Stage II non-microscopic, any grade, pNx/N0, with or without LVSI.
 - 171 ○ Stage III, any grade, pNx/N0-2, with or without LVSI.
- 172 • Patient consent must be appropriately obtained in accordance with applicable local and
173 regulatory requirements. Each patient must sign a consent form prior to enrolment in the trial
174 to document their willingness to participate. A similar process must be followed for sites
175 outside of Canada as per their respective cooperative group's procedures.
- 176 • Patient is able (i.e., sufficiently fluent) and willing to complete the QOL and/or health utility
177 questionnaires in either English, French or a validated language. The baseline assessment must
178 be completed within the required timelines, prior to enrolment. Inability (lack of
179 comprehension in English or French, or other equivalent reason such as cognitive issues or lack
180 of competency) to complete the questionnaires will not make the patient ineligible for the
181 study. However, ability but unwillingness to complete the questionnaires will make the patient
182 ineligible.
- 183 • Patients must be accessible for treatment and follow up. Patients enrolled on this trial must be
184 treated and followed at the participating center. Investigators must assure themselves the
185 patients enrolled on this trial will be available for complete documentation of the treatment,
186 adverse events, and follow-up.

- 187 • Patients must agree to return to their primary care facility for any adverse events which may
188 occur through the course of the trial.
- 189 • In accordance with CCTG policy, protocol treatment is to begin within 10 weeks of
190 hysterectomy/bilateral salpingo-oophorectomy.
- 191
- 192 * Pelvic lymph node surgical assessment (sentinel or full lymphadenectomy) is required for grade 3
193 or stage II. Para-aortic lymphadenectomy is not mandated.
- 194 ^ Substantial LVSI is defined as ≥ 3 foci as per College of American Pathologists' reporting guidelines.
195
- 196 Exclusion criteria
- 197 • Prior chemotherapy for EC
- 198 • Isolated tumor cells identified in lymph node(s) for the low risk group
- 199

200 **2. Requirements for surgery, radiotherapy and chemotherapy**

201

202 The RAINBO program imposes some requirements on participating centers for surgery,
203 external beam radiotherapy and/or vaginal brachytherapy and chemotherapy if these treatments
204 are given in the four clinical trials.

205 *Surgery*

206 The standard surgical procedure is i) open, ii) laparoscopic, or iii) robot-assisted total
207 abdominal hysterectomy with bilateral salpingo-oophorectomy (BSO) and biopsy of any clinically
208 suspicious lesions (such as peritoneal deposits or lymph nodes) with histological examination.
209 Performance of diagnostic staging lymphadenectomy and/or sentinel node biopsy are at the
210 discretion of the participating center or group.

211 Lymph node debulking with or without para-aortic lymph node sampling is recommended in
212 case of macroscopic positive pelvic nodes and/or para-aortic nodes, as detected on pre-surgical CT
213 or MRI scans or intra-operatively. Other extra-uterine tumor deposits should also be completely
214 removed.

215 At the completion of the operation there should be no remaining macroscopic tumor.

216

217 *External beam radiotherapy*

218 The dose schedule for adjuvant EBRT should range between 45-48.6 Gy, with fraction size of
219 1.8-2.0 Gy per fraction, 5 fractions a week. Treatment should preferably be started within 6 to 8
220 weeks after surgery, but no later than 10 weeks. Treatment breaks should be avoided, and
221 treatment time for EBRT should be kept within 5-6 weeks. Treatment prolongation due to public
222 holidays and machine maintenance should not exceed 2-4 days.

223 External beam radiotherapy will be given according to the center's standard policy and
224 technique. Pelvic or pelvic and para-aortic radiotherapy is used according to the extent of the tumor
225 involvement. The clinical target volume (CTV) includes the proximal half of the vagina, the
226 paravaginal / parametrial soft tissues, and the internal and external iliac lymph node regions, as well
227 as the distal third to half of the common iliac lymph node region. Inclusion of the subaortic pre-
228 sacral nodes is recommended for tumors with pelvic lymph node involvement, cervical stromal
229 involvement, or vaginal involvement.

230 Contouring of the CTV should be done according to literature data and atlases and taking
231 institutional preferences and practices into account. Useful guidelines and contouring atlas can be
232 found at: RTOG website (NRG Oncology/RTOG consensus guidelines), and in the publication by

233 Small.¹ The organs at risk to be contoured are the bladder, rectum, sigmoid, bowel bag (excluding
234 sigmoid, according to the EMBRACE-II recommendations), and the femoral heads.²

235 In case of external or internal iliac lymph node involvement, the common iliac lymph node
236 regions are to be included up to the aortic bifurcation. In case of common iliac node involvement,
237 the target volume should include at least the lower para-aortic region. In case of para-aortic
238 involvement, the para-aortic lymph node region should be extended to include the higher para-
239 aortic region at least 1 cm above the renal vessels (margin of at least 2 cm above the highest lymph
240 node region involved).¹ If a complete bilateral lymphadenectomy has been performed with at least
241 12 lymph nodes (with nodes from all sites: left and right external, internal and common iliac regions
242 and lower para-aortic nodes) and all lymph nodes are free of tumor at histopathologic evaluation,
243 the upper border of the CTV is at the start of the (common) iliac bifurcation.

244 CT planning will be used with individual target volume and organ-at-risk contouring for all
245 patients. Treatment planning will be done using intensity-modulated radiotherapy (IMRT) or
246 volumetric arc therapy (VMAT) or tomotherapy with appropriate QA. CT planning scans in treatment
247 position with (comfortably) full bladder should be obtained; preferably also an empty bladder scan is
248 obtained and merged to determine an internal target volume (ITV) accounting for movement of the
249 vaginal vault region.¹ The full bladder scan should be used for treatment planning. Dose
250 specification, planning and homogeneity requirements should be done according to ICRU-report 83.³
251 The dose in the CTV, PTV and organs at risk should be recorded and DVHs should be generated. At
252 least 95% of the prescribed dose should cover >98% of the PTV (aiming for >99%). The maximum
253 dose received by 2% of the PTV should not exceed 107 % of the prescribed dose. Dose constraints
254 for the organs at risk are provided below in Supplemental Table 1.

255 The Planning Target Volume (PTV) consists of the CTV/ITV with a 5-7 mm margin, depending
256 on the type of position verification and institutional practices. Daily position verification using cone
257 beam CT is strongly recommended. A 'library of plans' technique with daily selection of the most
258 appropriate treatment plan is permitted if standard for the treating center.

259

260

261 **Supplemental Table 1. RAINBO dose aims and constraints for external beam radiotherapy**

Organ at risk	Dose volume	Limit	Type
Bowel			
- RT pelvic area	V30Gy	< 500 cc	constraint
- RT pelvic + PAO area	V30Gy	< 650 cc	constraint
	V30Gy	< 350 cc	aim
	V40Gy	< 250 cc	aim
Sigmoid	V45Gy	< 60%	aim
	V50Gy	< 50%	aim
Bladder	V40Gy	< 75%	aim
	V30Gy	< 85%	aim
Rectum	V30Gy	< 95%	aim
	V40Gy	< 85%	aim
Spinal canal	V48Gy	< 0.03 cc	constraint
Femur head	Dmax	< 50 Gy	aim
Kidney	Dmean	< 15 Gy	constraint
		< 10 Gy	aim
	V12Gy	< 55%	constraint
Body	Dmax	107%	constraint

262 *Definition of abbreviations: D = dose; PAO = para-aortic; RT = radiotherapy; V = volume*

263

264 *Vaginal brachytherapy*

265 A brachytherapy boost is to be considered in patients with documented cervical stromal
 266 involvement and/or substantial LVSI. Brachytherapy should be either incorporated within the last
 267 week of EBRT (not giving both on the same day) or be given in the first week after completion of
 268 EBRT (HDR sessions ideally immediately following completion of EBRT). Overall treatment time for
 269 radiotherapy (EBRT and brachytherapy) should not exceed 50 days.

270 Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according
 271 to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm,
 272 with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and
 273 pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy
 274 at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm). Example of a
 275 schedule: HDR 8-10 Gy in 2 fractions.

276

277 *Radiotherapy quality control*

278 The participating centers of the RAINBO program have extensive experience with quality
 279 assessment of external beam radiotherapy and brachytherapy in clinical trials for EC because of the
 280 proceeding series of PORTEC trials.⁴⁻⁶ In addition, many centers have participated in the EMBRACE^{2,7}

281 and INTERLACE trials (NCT0566240) on cervical cancer which are renowned for their stringent EBRT
282 and brachytherapy planning criteria and intensive assessments. This protocol is based on those
283 experiences and provides the participating centers with a detailed description of the requirements
284 for EBRT and brachytherapy that should fit current practices. Therefore, there will be no formal
285 radiotherapy quality assessment control in the RAINBO trials.

286

287 *Chemotherapy*

288 Chemotherapy in the RAINBO program is preferably given concurrent and adjuvant
289 according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and
290 fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous
291 carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.⁶

292

293 **3. Histopathology and molecular testing**

294 *Histopathology*

295 One of the unique aspects of the RAINBO program is that all histological grades and almost
296 all histological subtypes of endometrial cancer can enter the program. Histologic subtypes that are
297 eligible for the RAINBO program are: endometrioid (all grades), serous, clear cell, carcinosarcomas,
298 un-/dedifferentiated endometrial carcinomas and mixed-epithelial carcinomas. Histologic subtypes
299 that are excluded are: gastric-type endometrial carcinomas and mesonephric-like endometrial
300 carcinomas. Central histopathological review is not a requirement for entering into the RAINBO
301 program.

302 Assessment of cervical stromal tumor invasion must be performed by microscopy as part of
303 the pathological staging of the surgical resection specimen; only cases with unequivocal stromal
304 involvement should be classified as stage II.

305 Substantial LVSI can be diagnosed on H&E slides without the need for additional
306 immunostains. Substantial LVSI is defined as widespread invasion of tumor emboli into vascular
307 spaces at and beyond the invasive front of the tumor. It is most often identified in a spray-like
308 pattern in the myometrium and frequently accompanied by vascular-associated immune-infiltrate.
309 Although the extent of LVSI may vary per H&E slide, LVSI foci are often found in multiple slides. If the
310 extent of LVSI is limited to <4 vessels, it is regarded as focal LVSI. For some of the RAINBO trials at
311 least substantial LVSI must be present for some tumor stages. Substantial LVSI is defined as LVSI in 4
312 or more vessels.⁸

313

314 *Molecular classification*

315 Prior to inclusion in one of the RAINBO trials complete assessment of the molecular
316 classification must be performed on the EC specimen. This can be either the tumor containing
317 hysterectomy (preferred) specimen or the preoperative specimen. Molecular classification includes
318 mutational status assessment of the exonuclease domain of DNA polymerase epsilon (*POLE*), MMR
319 immunohistochemistry (IHC) and p53 IHC or TP53 sequencing. These tests should be performed in a
320 (pathology) laboratory with ISO-15189 accreditation (or equivalent certification). For molecular class
321 assignment the algorithm of the WHO 2020 classification is used.⁹ Cases with more than one
322 classifying feature (sometimes referred to as multiple or double classifiers) should be classified as
323 follows:

324 i) EC with pathogenic *POLE* mutations are classified as *POLE*mut EC regardless of the MMR and
325 p53 status,

- 326 ii) EC without pathogenic *POLE* mutations and mismatch repair deficiency are classified as MMRd
 327 EC, regardless of the p53 status,
 328 iii) EC without pathogenic *POLE* mutations that are mismatch repair proficient and have p53 an
 329 abnormal IHC pattern and/or pathogenic *TP53* mutations are classified as p53abn EC, and
 330 iv) EC without pathogenic *POLE* mutations that are mismatch repair proficient and have no p53
 331 abnormalities are classified as NSMP.

332

333 *POLE* status

334 There is a variety of validated technologies available to assess the status of *POLE* in EC.
 335 Acceptable technologies for RAINBO include: 1) targeted NGS covering exon 9-14, 2) Sanger
 336 sequencing covering exon 9-14. Use of other technologies such as *POLE* hotspot analysis by for
 337 example (multiplex) qPCR or SnAPShot could be granted by the RAINBO steering committee after
 338 proper validation against golden standard NGS. For all techniques, adequate assessment of
 339 preferably the mutational status of all 11 hotspots, but at least the five most frequent hotspots
 340 within the exonuclease domain of *POLE* are required (Table 2.1). *POLE* variants outside the
 341 exonuclease domain are not considered.

342 **Supplemental table 1. Pathogenic *POLE* EDM mutations in the exonuclease domain**

Order of frequency	Protein change	Nucleotide substitution	Assessment for RAINBO program	Interpretation molecular class
1.	P286R	c.857C > G	Mandatory	<i>POLE</i> -mutant
2.	V411L	c.1231G > T or C	Mandatory	<i>POLE</i> -mutant
3.	S297F	c.890C > T	Mandatory	<i>POLE</i> -mutant
4.	S459F	c.1376C > T	Mandatory	<i>POLE</i> -mutant
5.	A456P	c.1366G > C	Mandatory	<i>POLE</i> -mutant
6.	F367S	c.1100T > C	Strongly recommended	<i>POLE</i> -mutant
7.	L424I	c.1270C > A	Strongly recommended	<i>POLE</i> -mutant
8.	M295R	c.884T > G	Strongly recommended	<i>POLE</i> -mutant
9.	P436R	c.1307C > G	Strongly recommended	<i>POLE</i> -mutant
10.	M444K	c.1331T > A	Strongly recommended	<i>POLE</i> -mutant
11.	D368Y	c.1102G > T	Strongly recommended	<i>POLE</i> -mutant

343 According to León-Castillo et al. J Pathol 2020¹⁰

344

345 Besides the pathogenic *POLE* mutations in the exonuclease domain listed in Supplemental
 346 table 1, León-Castillo et al. (J Pathol 2020¹⁰) also defined a list of non-pathogenic *POLE* mutations
 347 and variants of unknown significance in the exonuclease domain of *POLE*. These neither affect the
 348 assessment of the *POLE* status nor assignment of the molecular class. In case of the detection of a
 349 novel *POLE* variant within the exonuclease domain that is not described by León-Castillo et al. (J
 350 Pathol, 2020), the case should be regarded as *POLE* wildtype.

351 For the inclusion into the *POLE*mut-BLUE trial, the EC must contain a pathogenic variant in
352 the exonuclease domain of *POLE*. If the assessment of the *POLE* status has failed or is not available,
353 the patient cannot enter the RAINBO program. Assignment of an EC as being *POLE*mut EC is
354 independent of any of the other test results as described in Supplemental figure 1.

355 In the unlikely case that a patient has a pathogenic *POLE* mutation but assessment of MMR
356 status and/or p53 status has failed, the patient is not eligible for participation in the RAINBO
357 program either, even though such patients can be classified into the *POLE*mut molecular class
358 according to the WHO 2020 algorithm.

359

360 *MMR status*

361 For the purpose of all RAINBO trials MMR status must be determined by IHC. When MMR-
362 IHC is performed, MSH6 and PMS2 (two-antibody approach) is the minimal requirement. Cases with
363 positive nuclear staining of MSH6 and PMS2 can be regarded MMR proficient. In all cases with
364 ambiguous MSH6 and/or PMS2 staining, MLH1 and MSH2 are required for final MMR status
365 assignment. A cancer is considered MMR deficient when at least one of the MMR proteins show loss
366 of expression with positive internal control. In most MMR deficient cases, the complete tumor will
367 show loss of expression; infrequently a sub-clonal loss of MMR expression can be observed. In cases
368 of sub-clonal/partial MMR protein loss there might be a pathogenic driver mutation in *POLE*. If the
369 EC appears to be *POLE*-wild type, the cancer is considered MMR deficient when >10% of the tumor
370 volume shows sub-clonal loss.

371 In ambiguous MMR-IHC cases or in case of failed MMR IHC, it is recommended to perform
372 an analysis of MSI status for definitive assignment. MSI-high is then considered equal to MMRd. If
373 both tests failed, then MMR status and final molecular class cannot be assigned, and the patient is
374 not eligible for inclusion in the RAINBO trials. For the assignment of an EC as MMR deficient, *POLE*
375 status must be wildtype as can be deduced from Supplemental Figure 1.

376 The RAINBO program encourages to execute the Lynch Syndrome triage following
377 international guidelines.¹¹ It is therefore recommended to perform MLH1 methylation assay in cases
378 with loss of MLH1/PMS2 expression in order to pre-screen patients for germline testing. The MLH1
379 methylation assay is however not a requirement for entering in one of the RAINBO trials, as it has no
380 impact on the molecular EC classification.

381

382 *p53 status*

383 p53 status is preferably determined by IHC. Abnormal p53 IHC is defined as 1) complete loss
384 of expression with positive internal control or 2) strong nuclear and/or 3) cytoplasmic

385 overexpression. When the p53-IHC stain is well interpretable, TP53 sequencing is not required for
386 molecular subgroup assignment. In cases with an ambiguous IHC result, p53 status cannot be
387 assigned by p53 IHC alone. In these instances, it is recommended to use sequencing (NGS or Sanger)
388 to assign p53 status. Upfront assessment of p53 status by *TP53* mutational analyses (e.g., by NGS or
389 Sanger) instead of IHC is allowed under the condition that 1) the complete *TP53* gene is covered by
390 the sequencing panel and 2) only pathogenic p53 mutations are considered. We refer to the
391 following two public databases to determine the pathogenicity of any detected TP53 mutations:

- 392 • International Agency for Research on Cancer (IARC) TP53 database¹²
393 (<https://p53.iarc.fr/TP53GeneVariations.aspx>)
- 394 • ClinVar database¹³
395 (<https://erepo.clinicalgenome.org/evrepo/ui/classifications?matchMode=exact&gene=TP53>)

396 Sometimes sequencing detects *TP53* mutations that are not present in these two databases.
397 Often these are secondary mutations in a MMRd or *POLE*mut EC that can be disregarded. If the
398 tumor is MMR proficient and *POLE* wild type, we recommend performing p53 IHC and rely on the
399 IHC result to classify the EC.

400 If both IHC and sequencing of the whole TP53 gene are performed upfront, discordance
401 between these two techniques can be observed in 7.7-9.3% across all EC molecular types and in 4.9-
402 5.5% in *POLE*-wild type and MMR-proficient EC.^{14 15} The majority of these discordant cases can be
403 resolved by reviewing the p53 IHC (missed sub-clonal areas, missed “null=pattern”?) and reviewing
404 the sequencing data (is the variant truly pathogenic, has there not been a mix-up, what is the allele-
405 frequency?). If in such cases IHC shows convincing abnormality and sequencing did not detect a
406 pathogenic variant, the cases should be considered p53 abnormal. If sequencing shows a pathogenic
407 *TP53* variant but IHC shows a convincing wild type staining pattern, other aspects can be considered
408 for final molecular subgroups assignment. One can for example look at the other molecular
409 alterations (Her2 amplification, PTEN status, histologic subtype) to support a subgroup assignment.
410 We estimate that this will only be needed in ~1% of cases and we advise to send these specific cases
411 out for consult to the national RAINBO pathology expert for assistance with the interpretation and
412 assignment of molecular class.

413 Abnormal p53 patterns may be observed in only a part of the tumor while the remaining
414 tissue shows wild type p53 staining; this is called sub-clonal abnormal p53 expression and has been
415 observed in 5-7% of high-risk EC.^{14 15} This phenomenon is often the result of secondary p53
416 mutations and usually occurs in *POLE* mutant or MMRd EC. According to the WHO 2020 guideline,
417 those cases must be assigned to respectively the *POLE*mut or MMRd EC molecular class. Hence, sub-
418 clonal p53 abnormality in *POLE*mut and MMRd EC does not affect eligibility for respectively the

419 RAINBO-BLUE and RAINBO-GREEN trials. However, in *POLE*-wild type and MMR proficient EC, the
420 presence of sub-clonal p53 abnormality will determine whether the EC is classified as a p53abn EC or
421 a NSMP EC. Because this situation is very rare (<1% of EC) current literature does not provide solid
422 evidence for a threshold for the percentage of sub-clonal p53 abnormality.¹⁵ For the RAINBO
423 program, it was decided based on consensus that *POLE*-wild type, MMR-proficient EC with sub-
424 clonal p53 abnormality in >50% of the tumor should be regarded as p53abn EC and are eligible for
425 participation in the RAINBO-RED trial. *POLE* wild type, MMR-proficient EC with sub-clonal p53
426 abnormality in <10% of the tumor should be regarded as NSMP EC and are eligible for participation
427 in the RAINBO NSMP-ORANGE trial. The very small group of patients who have a *POLE* wild type,
428 MMR proficient EC with 10-50% sub-clonal p53 abnormality cannot be assigned to a molecular class
429 and are not eligible for participation in any of the 4 RAINBO clinical trials. Nonetheless, collection of
430 data on clinical outcome and FFPE tumor blocks of this specific subgroup is encouraged to enable
431 future research on molecular class assignment.

432 For further details on the interpretation of p53-IHC we refer to the following publications:
433 Köbel et al. 2016¹⁶, Singh et al. 2020¹⁴ and Vermij et al. 2022.¹⁵ To finally assign an EC as p53abn EC
434 the EC must show abnormal p53 expression and be MMR proficient and *POLE* wild type.

435

436 *ER status*

437 ER should be assessed using immunohistochemistry of a whole tumor slide in women who
438 have NSMP EC (hence *POLE* wild type and MMR proficient and p53 wild type) to determine eligibility
439 for the NSMP-ORANGE trial. ER is considered positive if expression is observed in >10% of the tumor
440 tissue. Women with NSMP EC with ER positivity can be considered for inclusion in the RAINBO
441 NSMP-ORANGE trial.

442

443 *Allocation to molecular class-based trial*

444 EC patients that are eligible based on the in- and exclusion criteria of the RAINBO program
445 (listed in the main text of the article), and who are molecularly classified as described above should
446 be considered for inclusion in the RAINBO trial of their molecular type. The patients should be
447 screened according to the inclusion- and exclusion criteria of the appropriate trial (Supplementary
448 Data 1) and be counselled and asked for informed consent if eligible.

449

450 **4. Sample size and power**

451

452 *The p53abn-RED trial*

453 The trial has a superiority design wherein eligible patients will be randomized (1:1) to
454 olaparib (300 mg per day, orally) starting after chemoradiation for a total of 2 years vs.
455 chemoradiation only. Based on an expected RFS rate of 64.6% at 3 years in control group (PORTEC-
456 3¹⁷), 197 events will allow to test for a hazard ratio of at least 0.67 (i.e., RFS rate of 74.6% at 3 years
457 in treatment group) with a power of 80% or more, based on a 5%-bilateral log rank test, and
458 including an interim analysis for efficacy. An interim analysis will be performed with group-
459 sequential design when 70% of the information will be accrued, i.e., after 139 RFS events..
460 Considering an exponential survival, an accrual duration of 36 months and an additional follow-up
461 period of 30 months, 526 patients will need to be included overall. Considering a potential dropout
462 rate of 5%, the number of patients to include is set to 554.

463

464 *The MMRd-GREEN trial*

465 The trial has a superiority design wherein eligible patients will be randomized (1:1) to either
466 external beam radiotherapy concurrent with the PD-L1 inhibitor durvalumab (AstraZeneca) up to
467 one year or external beam radiotherapy only. A two-sided log-rank test with an overall sample size
468 of 309 subjects (154 in the control group and 155 in the experimental group) achieves 80.0% power
469 at a 0.05 significance level to detect a hazard ratio of 0.58 when the proportion surviving in the
470 control group is 0.65 and in the experimental group is 0.78. After correction for drop-out, the
471 required sample size is 316 subjects. Accrual duration is projected to be 30 months with a 30-month
472 additional follow-up period. No interim analysis is planned, but an independent data monitoring
473 committee will continuously monitor recurrences and adverse events in the trial.

474

475 *The NSMP-ORANGE trial*

476 The trial has a non-inferiority design wherein eligible patients will be randomized (1:1) to
477 radiotherapy with hormone therapy (medroxyprogesterone or medroxyprogesterone acetate) for 2
478 years or chemoradiation. The sample size calculation is based on the stage III NSMP EC patients
479 participating in the PORTEC-3 trial who had a 3-year RFS of 82.5% after chemoradiation.¹⁷ A non-
480 inferiority margin of 7.5 percentage points is of interest, to exclude a 3-year RFS rate of below 75%
481 in the experimental arm, representing a hazard ratio (HR) of 1.495. This margin was chosen after
482 considering outcomes through RT alone in PORTEC-3 and is in-line with the perspectives of both
483 patients and clinicians with regards to the required benefits for adjuvant chemotherapy to be

484 worthwhile in EC.¹⁸ Patients will be recruited over 5 years with 3 years of additional follow-up to
485 observe 153 RFS events, for 80% power at the one-sided 5% significance level after allowing for up
486 to 5% dropout. As the planned recruitment period is relatively long, fertility analyses are
487 incorporated into the study. Conditional power will be calculated and presented to the independent
488 data monitoring committee on an annual basis; if this drops below 15% then a further check will be
489 made after 6 months and if conditional power remains <15% then the IDMC may recommend closing
490 the trial.¹⁹

491

492 *The POLEmut-BLUE trial*

493 In the POLEmut-BLUE trial eligible patients with select stage I-II POLEmut EC in the main
494 study cohort (see Supplementary Data 1) will receive no adjuvant therapy. Patients will be recruited
495 over 36 months with 36 months of additional follow-up, which will give an expected total person-
496 years of 506. Assuming a 3-year pelvic recurrence rate of 1%, the upper 95% confidence limit for the
497 true 3-year pelvic recurrence rate would be 2.4%; a true 3-year pelvic recurrence rate of 5%, which is
498 considered an unacceptable high risk, can be ruled out with more than 95% confidence. If the
499 observed 3-year pelvic recurrence rate is higher at 2%, then the upper 95% confidence limit for the
500 true 3-year pelvic recurrence rate would be 3.7% and a rate of 5% or higher can still be rejected at
501 the one-sided 5% significance level. Interim analysis for fertility will be carried out when half of the
502 person-years of follow-up have been observed, corresponding to approximately 253 person-years.
503 Final analysis will be performed when 506 person-years of follow-up are observed, which is foreseen
504 at 3 years after the inclusion of the last patient. In addition, higher-risk POLEmut EC patients will be
505 accrued into the exploratory cohort, offering observation or radiation alone (estimated sample size
506 25) for descriptive analysis.

507

508 *RAINBO overarching research program*

509 In the overarching RAINBO research program, predefined comparisons between
510 personalized molecular profile-based treatment and standard treatment will be made including all
511 participants of the four RAINBO sub-trials. To determine whether personalized treatment for EC is
512 more effective, less toxic and provides a better QoL than standard treatment, all patients who have
513 received molecular profile-directed adjuvant treatment (Group A) will be pooled and compared to
514 the pooled data of all patients who have received standard treatment (Group B). The projected
515 sample size of the overarching research program is around 1600. Power calculations for the different
516 endpoints were based on a sample size of 700 cases per group.

517

518 Treatment efficacy

519 It is estimated that we will have 80% power (alpha 0.01) to detect a true hazard ratio of
520 0.833 or 1.201 based on 700 participants in each group; and 90% power to detect a true HR of .814
521 or 1.229. Assumptions: accrual time of 4 years, additional follow-up time of 3 years and a median
522 RFS with the standard treatment of 5.04 years (based on the PORTEC-3 trials' pooled estimate). The
523 relation between the power and detectable difference is presented in power graph 1 of
524 Supplemental figure 2.

525

526 Treatment toxicity

527 It is estimated that we will have 80% or more power (alpha 0.01) to detect a true difference
528 in grade ≥ 2 morbidity at 3 years if it occurs in less than 23.7% or more than 40.9% of the patients in
529 group B. Assumptions: 700 patients are included in each group, the cumulative incidence of grade
530 ≥ 2 morbidity is 32% at 3 years with the standard treatment (based on the chemoradiation group in
531 PORTEC-3), using Fisher's exact test to evaluate this null hypothesis. Alternatively, if the cumulative
532 incidence of grade ≥ 2 morbidity is assumed to be 24% at 3 years with the standard treatment (based
533 on the radiotherapy group in PORTEC-3), we will have at least 80% power to detect a true difference
534 if it occurs in less than 16.5% or more than 32.4% of the patients in group B. The relation between
535 the power and detectable difference is presented in power graph 2 of Supplemental figure 2.

536

537 Health-related quality of life

538 It is estimated that we will have 80% or more power (alpha 0.01) to detect a true difference
539 in the EORTC QLQ-C30 scale score for fatigue at 3 years if the difference between group A and B is
540 6.1 points (scale of 0 to 100) or more. Assumptions: 700 patients are included in each group, the
541 standard deviation of the scale score for fatigue in the control population is 33.4 (based on the
542 reference values for cervical cancer patients of the EORTC-QLQ) and the t-test is used to evaluate
543 this null hypothesis. Alternatively, we have 80% or more power to detect a true difference in fatigue
544 of 3.7 points or more if the SD in the control population is assumed to be equal to the Dutch
545 reference population (SD=20, according to van de Poll et al. 2011).²⁰ The relation between the power
546 and detectable difference is presented in power graph 3 of Supplemental figure 2.

547

548


549 Cost-utility

550 Disease-related health care costs will be estimated for Group A and B based on the collected
 551 data on received adjuvant treatment, treatment for first recurrence and severe toxicity. Costs of
 552 molecular profiling will only be included in group B. Quality-adjusted life years will be estimated with
 553 individual follow-up times corrected for quality by linear interpolation of utility values deduced from
 554 the EORTC QLQ-C30 questionnaires using the EORTC QLU-C10D.^{21,22} Cost-effectiveness acceptability
 555 curves will be used to plot the probability that tailored treatment is more cost-effective than
 556 standard treatment as a function of willingness to pay. Sensitivity analysis will include alternative
 557 methodology for utility value assessment by the EORTC 8D.^{23,24}

558
 559



Power for hypothesis testing in the RAINBO overarching research program

560 **Supplemental figure 2. Power graphs RAINBO overarching research program**

561 *Definition of abbreviation: RFS = recurrence-free survival.*

562

563 **5. Statistical methods**

564

565 *The p53abn-RED trial*

566 The primary endpoint, 3-year RFS, will be estimated according to Kaplan-Meier's method and
567 compared between the two treatment groups using a Cox' proportional hazards model, with
568 adjustment for randomization stratification factors. Secondary endpoints will be analyzed using
569 competing risk models except for OS, which will be analyzed using the same methodology as RFS.

570

571 *The MMRd-GREEN trial*

572 The primary endpoint, 3-year RFS will be assessed according to Kaplan-Meier's methodology
573 and compared between groups using a log-rank test when a median follow-up of three years has
574 accrued. Other time-to-event analysis, including toxicity will be performed using similar methods.
575 Health-related quality of life of patients will be analysed using linear mixed models and generalized
576 estimating equations. Cross-sectional analysis of QoL will be performed at 6 months, 12 months, and
577 36 months using linear regression for scale scores and logistic regression for item scores after
578 dichotomization.

579

580 *The NSMP-ORANGE trial*

581 The primary endpoint will be described using Kaplan-Meier's method and analyzed using a
582 Cox' proportional hazards model. The interpretation of non-inferiority will be based on the 95%
583 confidence interval. Similar methods will be used for other time-to-event endpoints. Toxicity will be
584 described using proportions and exact 95% confidence intervals and compared between groups
585 using χ^2 /Fisher's exact tests as appropriate. Quality of life outcomes will be analyzed using mixed
586 models.

587

588 *The POLEmut-BLUE trial*

589 In the POLEmut-BLUE trial, the primary endpoint 3-year pelvic recurrence will be derived
590 from a competing risk analysis with death due to any cause as competing event and censoring of
591 alive patients without pelvic recurrence. If the upper 95% confidence limit is less than 5% it will be
592 concluded that the risk of pelvic recurrence at 3 years with molecular-tailored de-escalated adjuvant
593 treatment is acceptable. The same competing risk-based approach is also used to estimate isolated
594 vaginal recurrence and distant metastasis rates at 3 years and associated 90% confidence intervals.
595 Kaplan-Meier method will be used to estimate 3-year rates of recurrence-free, EC-specific, and
596 overall survivals and associated 90% confidence interval. In all these analyses, only those who have

597 complied with the recommendation for no or de-escalated adjuvant treatment will be included.
598 Patients' quality of life mean score for each subscale will be calculated at each time of assessment
599 from all patients who are assessed and compared to that observed in PORTEC-2²⁵, as a historical
600 control by a 2-sided one-sample t-test.

601

602 *The overarching RAINBO research program*

603 In the overarching research program, the oncological, survival and toxicity outcomes will be
604 analyzed according to Kaplan-Meier's methodology and compared using log-rank tests and
605 multivariable Cox' proportional hazards models. Longitudinal analysis of toxicity and quality of life
606 across the first 3 years after randomization will be done using linear mixed models and generalized
607 estimating equations. Cross-sectional analysis will be performed at 2-3 months, 6, 12 and 36 months
608 using linear and logistic regression. Disease-related health care costs will be estimated for Group A
609 and B based on the collected data on received adjuvant treatment, treatment for first recurrence
610 and severe toxicity. Costs of molecular profiling will only be included in group A. Quality-adjusted life
611 years will be estimated with individual follow-up times corrected for quality by linear interpolation
612 of utility values deduced from the EORTC QLQ-C30 questionnaires using the EORTC QLU-C10D^{21,22}.
613 Cost-effectiveness acceptability curves will be used to plot the probability that tailored treatment is
614 more cost-effective than standard treatment as a function of willingness to pay.

615

616

617 **6. RAINBO Research Consortium**

618

619 The RAINBO Research Consortium decided to publish this paper as a group, without any
 620 individual authorships. This is because of the ensemble of 4 clinical trials and an overarching and
 621 translational research program are the result of the interaction between experts of different
 622 disciplines; as opposed to the efforts of the individuals. Selecting a limited number of individuals for
 623 an authorship would not do justice to the efforts of all contributors that qualify for an authorship.
 624 Moreover, using individual authorships implies that only a handful of individuals will be assigned the
 625 most valued (first, second and last) authorships, which is incompatible with the number of lead
 626 investigators of the RAINBO program. The members of the RAINBO Research consortium on October
 627 4th 2022 are:

628

629 **Steering group (alphabetical)**

630 Bosse T¹, Creutzberg CL², Crosbie EJ³, Han K⁴, Horeweg N², Leary A⁵, Kroep JR⁶, McAlpine JN⁷, Powell
 631 ME⁸

632

633 **Translational committee (alphabetical)**

634 Blanc-Durand F⁵, Bosse T¹, de Bruyn M⁹, Church DN^{10,11}, Horeweg N², Koelzer VH^{12,13}, Kommos S¹⁴,
 635 Leary A⁵, McAlpine JN⁷, Singh N¹⁵

636

637 **Statistical committee (alphabetical)**

638 Bardet A^{16,17}, Counsell N¹⁸, Horeweg N², Putter H¹⁹, Tu D²⁰

639

640 **Advisory committee (alphabetical)**

641 Edmondson R³, Gordon C²¹, Ledermann J²², Morice P²³, MacKay H²⁴, Nijman H⁹, Nout RA²⁵, Smit
 642 VTHBM¹, White H²⁶.

643

644 **Country champions (alphabetical)**

645 Alexandre J^{27,28}, de Boer SM², Boere I²⁹, Cooper R³⁰, Ethier JL^{31,32}, Frenel JS³³, McGrane J³⁴, Taylor A³⁵,
 646 Welch S³⁶, Westermann AM³⁷

647

648 **Trial management (alphabetical)**

649 Dijkstra-van der Linden H³⁸, Farrelly L¹⁸, Feeney A¹⁸, Kaya M², Liu W²⁰, Melis A³⁸, Ngadjewa-Tchouatieu
 650 F³⁹, Parulekar W²⁰, Verhoeven-Adema K³⁸

651

652 **Writing committee**

653 Horeweg N², Powell ME⁸, Han K⁴, Kroep JR⁶, Blanc-Durand F⁵, Welch S³⁴, Bardet A^{16,17}, Counsell N¹⁸,
 654 Putter H¹⁹, Tu D²⁰, Singh N¹⁵, Church DN^{10,11}, Kommos S¹⁴, de Bruyn M⁹, Nijman H⁹, Creutzberg CL²,
 655 McAlpine JN⁷, Bosse T¹, Crosbie EJ³, MacKay H²³, Leary A⁵

656

657

658 **Affiliations of the participants of the RAINBO research consortium**

- 659 1. Department of Pathology, Leiden University Medical Center, the Netherlands
- 660 2. Department of Radiation Oncology, Leiden University Medical Center, the Netherlands
- 661 3. Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's
 662 Hospital, Manchester, United Kingdom
- 663 4. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network,
 664 University of Toronto, Radiation Oncology, Toronto, Canada
- 665 5. Department of Medical Oncology, Gustave Roussy Cancer Center, Université Paris Saclay, Cancer
 666 Medicine and Gynecological Tumor Translational Research Lab, Villejuif, France
- 667 6. Department of Medical Oncology, Leiden University Medical Center, the Netherlands
- 668 7. Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada

- 669 8. Department of Clinical Oncology, Barts Health NHS Trust, London, United Kingdom
670 9. Department of Gyneacology, University Medical Center Groningen, Groningen University, Groningen, the
671 Netherlands
672 10. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford,
673 the United Kingdom
674 11. Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom
675 12. Department of Pathology and Molecular Pathology, University Hospital Zürich, University of Zürich,
676 Zürich, Switzerland
677 13. Department of Oncology and Nuffield Department of Medicine, University of Oxford, Oxford, United
678 Kingdom
679 14. Department of Women's Health, University of Tübingen, Tübingen, Germany
680 15. Department of Cellular Pathology, Barths Health NHS Trust, London, the United Kingdom
681 16. Bureau of Biostatistics and Epidemiology, University Paris-Saclay, Gustave-Roussy, Villejuif, France
682 17. Oncostat U1018, Inserm, University Paris-Saclay, Ligue Contre le Cancer, Villejuif, France
683 18. Cancer Research UK and University College London Cancer Trials Centre, University College London,
684 London, United Kingdom.
685 19. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden
686 20. Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada
687 21. Patient Representative, Canadian Cancer Clinical Trials Group, Queen's University, Kingston, Ontario,
688 Canada
689 22. Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute and UCL Hospitals, London, the
690 United Kingdom
691 23. Department of Gynaecologic Surgery, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif,
692 France
693 24. Department of Medical Oncology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto,
694 Ontario, Canada
695 25. Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
696 26. Patient Representative, Peaches Patient Voices, Manchester, United Kingdom
697 27. Centre de Recherche des Cordeliers, Equipe labélisée Ligue Contre le Cancer, Sorbonne Université,
698 Université de Paris, INSERM, Paris, France.
699 28. Department of Medical Oncology, Hopital Cochin, Institut du Cancer Paris, Paris, France.
700 29. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
701 30. Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
702 31. Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Ontario, Canada
703 32. Department of Oncology, Queen's University, Kingston, Ontario, Canada.
704 33. Department of Medical Oncology, Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-
705 Herblain, France
706 34. Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, the United Kingdom.
707 35. Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, the United
708 Kingdom
709 36. Division of Medical Oncology, Western University, London, Ontario, Canada
710 37. Department of Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam,
711 the Netherlands
712 38. Comprehensive Cancer Center the Netherlands (IKNL), Leiden, the Netherlands
713 39. Clinical Research Department, Institute Gustave Roussy, Chevilly-Larue, France
714

715 **7. Supplementary references**

- 716 1. Small W, Jr., Bosch WR, Harkenrider MM, et al. NRG Oncology/RTOG Consensus Guidelines for
717 Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in
718 Postoperative Treatment of Endometrial and Cervical Cancer: An Update. *Int J Radiat Oncol Biol Phys*
719 2021;109(2):413-24. doi: 10.1016/j.ijrobp.2020.08.061 [published Online First: 2020/09/10]
720 2. EMBRACE_study_group. EMBRACE-II study protocol:
721 <https://www.embracestudy.dk/UserUpload/PublicDocuments/EMBRACE%20II%20Protocol.pdf>.
722 3. Hodapp N. [The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated
723 radiation therapy (IMRT)]. *Strahlenther Onkol* 2012;188(1):97-9. doi: 10.1007/s00066-011-0015-x
724 [published Online First: 2012/01/12]
725 4. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone
726 for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group.
727 Post Operative Radiation Therapy in Endometrial Carcinoma. *Lancet* 2000;355(9213):1404-11. doi:
728 10.1016/s0140-6736(00)02139-5 [published Online First: 2000/05/03]
729 5. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for
730 patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority,
731 randomised trial. *Lancet* 2010;375(9717):816-23. doi: 10.1016/S0140-6736(09)62163-2 [published
732 Online First: 2010/03/09]
733 6. de Boer SM, Powell ME, Mileschkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in
734 women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival
735 analysis of a randomised phase 3 trial. *Lancet Oncol* 2019;20(9):1273-85. doi: 10.1016/S1470-
736 2045(19)30395-X [published Online First: 2019/07/28]
737 7. Potter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical
738 cancer (EMBRACE-I): a multicentre prospective cohort study. *Lancet Oncol* 2021;22(4):538-47. doi:
739 10.1016/S1470-2045(20)30753-1 [published Online First: 2021/04/02]
740 8. Peters EEM, Leon-Castillo A, Smit V, et al. Defining Substantial Lymphovascular Space Invasion in
741 Endometrial Cancer. *Int J Gynecol Pathol* 2022;41(3):220-26. doi: 10.1097/PGP.0000000000000806
742 [published Online First: 2021/07/16]
743 9. WHO_Classification_of_Tumours_Editorial_Board. Female genital tumors. WHO Classification of Tumours,
744 5th Edition. 2020;4:252-66.
745 10. Leon-Castillo A, Britton H, McConechy MK, et al. Interpretation of somatic POLE mutations in endometrial
746 carcinoma. *J Pathol* 2020;250(3):323-35. doi: 10.1002/path.5372 [published Online First: 2019/12/13]
747 11. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients
748 with endometrial carcinoma. *Int J Gynecol Cancer* 2021;31(1):12-39. doi: 10.1136/ijgc-2020-002230
749 [published Online First: 2021/01/06]
750 12. Bouaoun L, Sonkin D, Ardin M, et al. TP53 Variations in Human Cancers: New Lessons from the IARC
751 TP53 Database and Genomics Data. *Hum Mutat* 2016;37(9):865-76. doi: 10.1002/humu.23035
752 [published Online First: 2016/06/23]
753 13. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation
754 and human phenotype. *Nucleic Acids Res* 2014;42(Database issue):D980-5. doi: 10.1093/nar/gkt1113
755 [published Online First: 2013/11/16]
756 14. Singh N, Piskorz AM, Bosse T, et al. p53 immunohistochemistry is an accurate surrogate for TP53
757 mutational analysis in endometrial carcinoma biopsies. *J Pathol* 2020;250(3):336-45. doi:
758 10.1002/path.5375 [published Online First: 2019/12/13]
759 15. Vermij L, Leon-Castillo A, Singh N, et al. p53 immunohistochemistry in endometrial cancer: clinical and
760 molecular correlates in the PORTEC-3 trial. *Mod Pathol* 2022 doi: 10.1038/s41379-022-01102-x
761 [published Online First: 2022/06/26]
762 16. Kobel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53
763 mutation in ovarian carcinoma. *J Pathol Clin Res* 2016;2(4):247-58. doi: 10.1002/cjp.2.53 [published
764 Online First: 2016/11/15]
765 17. Leon-Castillo A, de Boer SM, Powell ME, et al. Molecular Classification of the PORTEC-3 Trial for High-
766 Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. *J Clin Oncol*
767 2020;38(29):3388-97. doi: 10.1200/JCO.20.00549 [published Online First: 2020/08/05]
768 18. Post CCB, Mens JWM, Haverkort MAD, et al. Patients' and clinicians' preferences in adjuvant treatment for
769 high-risk endometrial cancer: Implications for shared decision making. *Gynecol Oncol*
770 2021;161(3):727-33. doi: 10.1016/j.ygyno.2021.03.004 [published Online First: 2021/03/14]
771 19. Jitlal M, Khan I, Lee SM, et al. Stopping clinical trials early for futility: retrospective analysis of several
772 randomised clinical studies. *Br J Cancer* 2012;107(6):910-7. doi: 10.1038/bjc.2012.344 [published
773 Online First: 2012/08/11]

- 774 20. van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-
775 sexuality items in the general Dutch population. *Eur J Cancer* 2011;47(5):667-75. doi:
776 10.1016/j.ejca.2010.11.004 [published Online First: 2010/12/08]
- 777 21. King MT, Costa DS, Aaronson NK, et al. QLU-C10D: a health state classification system for a multi-
778 attribute utility measure based on the EORTC QLQ-C30. *Qual Life Res* 2016;25(3):625-36. doi:
779 10.1007/s11136-015-1217-y [published Online First: 2016/01/23]
- 780 22. Kemmler G, Gamper E, Nerich V, et al. German value sets for the EORTC QLU-C10D, a cancer-specific
781 utility instrument based on the EORTC QLQ-C30. *Qual Life Res* 2019;28(12):3197-211. doi:
782 10.1007/s11136-019-02283-w [published Online First: 2019/09/06]
- 783 23. Lorgelly PK, Doble B, Rowen D, et al. Condition-specific or generic preference-based measures in
784 oncology? A comparison of the EORTC-8D and the EQ-5D-3L. *Qual Life Res* 2017;26(5):1163-76.
785 doi: 10.1007/s11136-016-1443-y [published Online First: 2016/11/11]
- 786 24. van Dongen-Leunis A, Redekop WK, Uyl-de Groot CA. Which Questionnaire Should Be Used to Measure
787 Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and
788 Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC
789 QLQ-C30. *Value Health* 2016;19(6):834-43. doi: 10.1016/j.jval.2016.05.008 [published Online First:
790 2016/10/08]
- 791 25. Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients
792 treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial
793 and comparison with norm data. *Eur J Cancer* 2012;48(11):1638-48. doi: 10.1016/j.ejca.2011.11.014
794 [published Online First: 2011/12/20]
- 795